Mylan (MYL) volatility flat into announces FDA approval of ANDAs for Glatiramer Acetate Injection
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform
October 4, 2017 10:44 AM EDTCowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.
With this approval the... More
Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval
October 4, 2017 7:27 AM EDTBTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy rating after the company received final FDA approval for its generic versions of Tevas (NASDAQ: TEVA) 20mg and 40mg... More
Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - Mizuho
October 4, 2017 7:02 AM EDTMizuho analyst Irina Koffler weighed in on Mylan's (NASDAQ: MYL) surprise approval for generic Copaxone after downplaying the possibility of a September approval and taking Copaxone out of its 2017 estimates. Koffler sees the news as "quite negative" Teva Pharma (NYSE: TEVA).
On Mylan, Koffler notes, "Importantly, Copaxone is AP rated (or therapeutically equivalent and substitutable), which makes it easier to... More
